AEterna Zentaris Inc. (USA) (NASDAQ:AEZSׁ) announced that it has started promoting Saizen® [somatropin (rDNA origin) for injection] in 25 territories in the United States, pursuant to its co‑promotion agreement signed this past May with EMD Serono, the U.S. biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany. Saizen® is a recombinant human growth hormone (r-hGH) registered in the U.S. for the treatment of growth hormone deficiency (GHD) in children and adults.

Under the agreement, Aeterna Zentaris details Saizen® to designated medical professionals in addition to EMD Serono’s current promotional activities. Payment to Aeterna Zentaris is based on new eligible patient starts on Saizen®, above an agreed-upon baseline.

Jude Dinges, Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented, “Our  sales force has initiated the promotion of Saizen®, a product with a broad portfolio of devices and comprehensive patient support services. We recognize the value of direct promotion in this category and we look forward to achieving increased market share and growth for Saizen® by significantly increasing the share-of-voice in support of Saizen®.”

David A. Dodd, Chairman and Chief Executive Officer of Aeterna Zentaris also stated, “This exciting start of the field promotion of Saizen® represents another important step in the transformation of Aeterna Zentaris into a commercially operating company. With its ongoing efforts in the development of electronic recombinant human growth hormone injection devices, EMD Serono is a leader in the field of growth hormone and offers us with Saizen®, a perfect fit with the endocrinology portfolio that we are developing. We will continue to look for products that we can co-promote, in-license or acquire as we build our portfolio and our commercial capabilities.” (Original Source)

Shares of Aeterna Zentaris closed last Friday at $0.2073. AEZS has a 1-year high of $1.54 and a 1-year low of $0.19. The stock’s 50-day moving average is $0.26 and its 200-day moving average is $0.46.

On the ratings front, Aeterna Zentaris has been the subject of a number of recent research reports. In a report issued on July 1, Maxim Group analyst Jason Kolbert reiterated a Buy rating on AEZS, with a price target of $2, which represents a potential upside of 864.8% from where the stock is currently trading. Separately, on May 21, H.C. Wainwright’s Swayampakula Ramakanth reiterated a Buy rating on the stock and has a price target of $1.25.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Swayampakula Ramakanth have a total average return of -2.9% and 19.2% respectively. Kolbert has a success rate of 35.8% and is ranked #3519 out of 3712 analysts, while Ramakanth has a success rate of 48.9% and is ranked #412.

AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinologyand women’s health.